CeriBell, Inc. (CBLL) Financial Ratios
4 years of historical data (2022–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
4.28
↑+26% vs avg
5yr avg: 3.39
30Y Low1.6·High5.2
ROE
↑
-30.8%
↓+54% vs avg
5yr avg: -66.7%
30Y Low-103%·High-31%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CBLL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
CeriBell, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Market Cap | $690M | $801M | $309M | — | — |
| Enterprise Value | $672M | $783M | $137M | — | — |
| P/E Ratio → | -12.45 | — | — | — | — |
| P/S Ratio | 7.75 | 9.00 | 4.73 | — | — |
| P/B Ratio | 4.28 | 5.16 | 1.62 | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CBLL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| EV / Revenue | — | 8.79 | 2.09 | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
CBLL Profitability
Margins and return-on-capital ratios measuring operating efficiency
CeriBell, Inc. earns an operating margin of -65.6%. A negative ROE of -30.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Gross Margin | 87.9% | 87.9% | 86.7% | 84.4% | 82.9% |
| Operating Margin | -65.6% | -65.6% | -60.7% | -66.4% | -139.0% |
| Net Profit Margin | -60.0% | -60.0% | -61.8% | -65.1% | -143.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ROE | -30.8% | -30.8% | -102.5% | — | — |
| ROA | -25.4% | -25.4% | -28.5% | -40.5% | -43.0% |
| ROIC | -56.2% | -56.2% | — | — | — |
| ROCE | -30.0% | -30.0% | -31.8% | -52.7% | -47.0% |
CBLL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $40M exceeds total debt of $22M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Debt / Equity | 0.14 | 0.14 | 0.11 | — | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.12 | -0.90 | — | — |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | -27.26 | -27.26 | -19.31 | -13.04 | -22.18 |
Net cash position: cash ($40M) exceeds total debt ($22M)
CBLL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
CeriBell, Inc.'s current ratio of 9.73x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 9.35x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 2.41x to 9.73x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Current Ratio | 9.73 | 9.73 | 16.73 | 2.41 | 8.09 |
| Quick Ratio | 9.35 | 9.35 | 16.19 | 2.13 | 7.68 |
| Cash Ratio | 8.30 | 8.30 | 14.96 | 1.60 | 6.92 |
| Asset Turnover | — | 0.45 | 0.29 | 0.77 | 0.30 |
| Inventory Turnover | 1.48 | 1.48 | 1.25 | 1.20 | 1.09 |
| Days Sales Outstanding | — | 61.69 | 60.67 | 64.20 | 74.56 |
CBLL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
CeriBell, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $37M | $12M | $23M | $23M |
Peer Comparison
Compare CBLL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CBLLYou | $690M | -12.5 | — | — | 87.9% | -65.6% | -30.8% | -56.2% | — |
 NVCR | $2B | -11.2 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 LIVN | $4B | -17.7 | 17.2 | 25.0 | 67.7% | 14.4% | -19.2% | 11.5% | 2.0 |
 INVA | $2B | 6.9 | 6.8 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 ACLS | $6B | 48.4 | 40.5 | 52.8 | 44.9% | 14.2% | 11.7% | 9.6% | 0.3 |
 MDT | $102B | 22.0 | 14.5 | 19.6 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 ABT | $153B | 11.5 | 16.0 | 24.0 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 PHG | $26B | 25.4 | 10.9 | 25.1 | 45.2% | 8.0% | 7.8% | 6.4% | 3.2 |
 GE | $371B | 43.5 | 38.0 | 51.1 | 36.8% | 19.1% | 45.3% | 24.7% | 2.1 |
 GEHC | $28B | 13.3 | 9.9 | 18.3 | 40.0% | 13.4% | 21.6% | 13.3% | 3.0 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
CBLL — Frequently Asked Questions
Quick answers to the most common questions about buying CBLL stock.
What is CeriBell, Inc.'s P/E ratio?
CeriBell, Inc.'s current P/E ratio is -12.5x. This places it at the 50th percentile of its historical range.
What is CeriBell, Inc.'s ROE?
CeriBell, Inc.'s return on equity (ROE) is -30.8%. The historical average is -66.7%.
Is CBLL stock overvalued?
Based on historical data, CeriBell, Inc. is trading at a P/E of -12.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are CeriBell, Inc.'s profit margins?
CeriBell, Inc. has 87.9% gross margin and -65.6% operating margin.